Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
ImmuPharma ( (GB:IMM) ) has provided an update.
ImmuPharma has announced groundbreaking advancements in its preclinical research, particularly concerning the P140 peptide and the pathogenesis of autoimmune diseases, which could lead to significant strides in personalized medicine. Despite recent fluctuations in its share price, ImmuPharma is not aware of any other commercial or operational reasons for these changes but remains committed to updating stakeholders on future developments.
More about ImmuPharma
ImmuPharma PLC is a specialty biopharmaceutical company that focuses on discovering and developing peptide-based therapeutics. The company’s primary focus is on novel peptide therapeutics for autoimmune diseases and anti-infectives, with its lead program, P140, targeting Systemic Lupus Erythematosus (SLE) and Chronic Idiopathic Demyelinating Polyneuropathy (CIDP).
YTD Price Performance: 356.43%
Average Trading Volume: 7,048,249
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £16.87M
For a thorough assessment of IMM stock, go to TipRanks’ Stock Analysis page.
